Cognitive Impairment Following Cardiac Arrest and Target Temperature Management

December 4, 2013 updated by: Region Skane

This is a steering group approved substudy to the Target Temperature Management trial (TTM, ClinicalTrials.gov Identifier: NCT01020916). TTM compares the effect of two strictly controlled temperature regimes for survivors of out-of-hospital cardiac arrest.

The primary aim of this sub-study is to compare the amount of cognitive impairment in cardiac arrest survivors treated with 33 degrees and 36 degrees and with a matched group of control patients with myocardial infarction.

Our secondary aims are:

  • To investigate the impact of cognitive impairment on our patients' ability to participate in society and their health related quality of life.
  • To investigate the relationship between our patients cognitive impairments and their relatives/informants health related quality of life and feelings of burden.
  • To test the hypothesis that the simple cognitive screening battery used in the TTM main trial is sensitive enough to detect all patients with significant cognitive disability.

Study Overview

Study Type

Interventional

Enrollment (Actual)

287

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen, Denmark
        • Rigshospitalet
      • Genova, Italy
        • San Martino Hospital
      • Pordenone, Italy
        • Santa Maria degli Angeli Hospital
      • Trieste, Italy
        • Ospedale Universitario di Cattinaria
      • Amsterdam, Netherlands
        • Onze Lieve Vrouwe Gasthuis
      • Amsterdam, Netherlands
        • Academisch Medisch Centrum (AMC)
      • Arnhem, Netherlands
        • Rijnstate Hospital
      • Leeuwarden, Netherlands
        • Leeuwarden Hospital
      • Gothenburg, Sweden
        • Sahlgrenska University Hospital
      • Gothenburg, Sweden
        • Sahlgrenska University Hospital, Thorax
      • Gothenburg, Sweden
        • Sahlgrenska University Hospital, Östra
      • Helsingborg, Sweden
        • Helsingborg Hospital
      • Karlstad, Sweden
        • Karlstad Central Hospital
      • Lund, Sweden
        • Skåne University Hospital, Lund
      • Malmoe, Sweden
        • Skåne University Hospital, Malmö
      • Örebro, Sweden
        • Orebro University Hospital
      • Bournemouth, United Kingdom
        • Royal Bournemouth Hospital
      • Cardiff, United Kingdom
        • University Hospital of Wales
      • London, United Kingdom
        • St Georges' Hospital
      • Reading, United Kingdom
        • Royal Berkshire NHS foundation trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 years or older
  • Out-of-Hospital Cardiac Arrest (OHCA)of presumed cardiac cause
  • Unconsciousness after sustained return of spontaneous circulation (ROSC)

Exclusion Criteria at time for inclusion in the TTM study:

  • Known bleeding diathesis
  • Suspected or confirmed acute intracranial bleeding
  • Suspected or confirmed stroke
  • Unwitnessed asystole
  • Known limitations in therapy and Do Not Resuscitate-order
  • Known disease making 180 days survival unlikely
  • Known prearrest status Cerebral Performance Category (CPC)3 or 4
  • Temperature <30°on admission

    • 4 hours (240 minutes) from ROSC to screening
  • Systolic blood pressure <80 mm Hg in spite of fluid loading/vasopressor and/or inotropic medication/intra aortic balloon pump
  • In-hospital cardiac arrest
  • OHCA of presumed non-cardiac arrest cause

Additional Exclusion criteria for the sub-study:

  • Disability to speak the site language well enough to complete tests without interpreter
  • Controls should never have suffered a cardiac arrest

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Cardiac Arrest 33°
survivors with temperature treatment 33°
ACTIVE_COMPARATOR: Cardiac Arrest survivors 36°
survivors with temperature treatment 36°

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rivermead Behavioural Memory Test (RBMT)
Time Frame: 180 days after Cardiac Arrest (CA) or Myocardial Infarction (MI)
Memory test
180 days after Cardiac Arrest (CA) or Myocardial Infarction (MI)
Frontal Assessment Battery (FAB)
Time Frame: 180 days after CA or MI
Screening of Executive functions
180 days after CA or MI
Symbol Digit Modalities Test (SDMT)
Time Frame: 180 days after CA or MI
Assess attention, mental speed and concentration
180 days after CA or MI

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mayo-Portland Adaptability Inventory-4 (MPAI-4)
Time Frame: 180 days after CA or MI
Self rating of impairments, adjustment, and participation (in the society)
180 days after CA or MI
Short-Form Questionnaire 36 version 2 (SF-36v2)
Time Frame: 180 days after CA or MI
Questionnaire of health-related quality of life, both for patient and informant/relative/caregiver
180 days after CA or MI
Zarit Burden Interview
Time Frame: 180 days after CA or MI
Questionnaire for caregiver/informant/relative's perception of burden
180 days after CA or MI
Hospital Anxiety and Depression rating Scale (HADS)
Time Frame: 180 days after CA or MI
Anxiety and Depression questionnaire
180 days after CA or MI
Two Simple Questions (TSQ)
Time Frame: 180 days after CA or MI
Self rating of everyday activities and cognition
180 days after CA or MI
Informant Questionnaire on Cognitive Decline (IQCODE)
Time Frame: 180 days after CA or MI
Patients cognitive functioning in everyday life, questionnaire completed by informant/relative/caregiver
180 days after CA or MI
MiniMental Status Examination (MMSE)
Time Frame: 180 days after CA or MI
General cognitive screening
180 days after CA or MI
Cerebral Performance Category (CPC)
Time Frame: 180 days after CA or MI
Scale for general neurological outcome
180 days after CA or MI
modified Rankin Scale
Time Frame: 180 days after CA or MI
Scale for general outcome
180 days after CA or MI

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Tobias Cronberg, MD, PhD, Department of Clinical Sciences, Lund University, Lund, Sweden and Department of Neurology, Skåne University Hospital, Lund, Sweden
  • Principal Investigator: Niklas Nielsen, MD,PhD, Department of Clinical Sciences, Lund University, Lund Sweden and Department of Anesthesia and Intensive Care, Helsingborg Hospital, Helsingborg, Sweden
  • Principal Investigator: Jesper Kjaergaard, MD, PhD, The Heart Centrem Copenhagen University, Copenhagen, Denmark
  • Principal Investigator: Janneke Horn, MD, PhD, Department of Intensive Care, Academic Medical Centrum, Amsterdam, Netherlands
  • Principal Investigator: Tommaso Pellis, MD, PhD, Intensive Care Unit Santa Maria Degli Angeli, Pordenonde, Italy
  • Principal Investigator: Matthew P Wise, MD, PhD, Adult Critical Care, University Hospital of Wales, Cardiff, Untied Kingdom
  • Study Director: Gisela Lilja, OT, Lund University Hospital, Lund, Sweden

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (ACTUAL)

November 1, 2013

Study Completion (ACTUAL)

November 1, 2013

Study Registration Dates

First Submitted

September 12, 2013

First Submitted That Met QC Criteria

September 17, 2013

First Posted (ESTIMATE)

September 20, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

December 5, 2013

Last Update Submitted That Met QC Criteria

December 4, 2013

Last Verified

August 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Injury

Clinical Trials on Temperature treatment

3
Subscribe